PTPN6 and colorectal carcinoma: Both of which significantly reduced the effects of regorafenib on growth inhibition in CRC cells, indicating that SHP-1 not only as a crucial player of regorafenib-induced growth inhibition, but also as a direct target of regorafenib by which enhanced SHP-1 tyrosine phosphatase activity downregulated p-STAT3Tyr705 directly.